Electrical stimulation of antagonist muscles after botulinum toxin type A for post-stroke spastic equinus foot. A randomized single-blind pilot study.


Journal

Annals of physical and rehabilitation medicine
ISSN: 1877-0665
Titre abrégé: Ann Phys Rehabil Med
Pays: Netherlands
ID NLM: 101502773

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 01 01 2019
revised: 10 06 2019
accepted: 10 06 2019
pubmed: 23 6 2019
medline: 28 1 2020
entrez: 23 6 2019
Statut: ppublish

Résumé

Botulinum toxin type A (BoNT-A) injection is an effective treatment for lower-limb spasticity and should be offered as first-line treatment for focal manifestations. Although its possible role has been hypothesized, the efficacy of electrical stimulation (ES) of antagonists of the injected muscles for improving clinical outcome after BoNT-A injection remains to be established. This randomized single-blind pilot study aimed to investigate the efficacy of ES of antagonist muscles as adjunct treatment after BoNT-A injection to plantar flexor muscles in hemiplegic patients with spastic equinus foot. After BoNT-A injection at triceps surae, patients were randomly allocated to 2 groups: group 1, single ES session on injected muscles plus 5 sessions of ES on antagonist muscles, and group 2, single ES session on injected muscles alone. Both groups underwent daily physical therapy for 60min for 2 weeks (5 days/week). Assessments were performed before treatment (T The 30 patients enrolled were randomly allocated to the 2 groups: 15 in group 1 and 15 in group 2. At T ES of antagonist muscles does not improve clinical outcomes in the post-stroke spastic equinus foot after BoNT-A injection.

Sections du résumé

BACKGROUND BACKGROUND
Botulinum toxin type A (BoNT-A) injection is an effective treatment for lower-limb spasticity and should be offered as first-line treatment for focal manifestations. Although its possible role has been hypothesized, the efficacy of electrical stimulation (ES) of antagonists of the injected muscles for improving clinical outcome after BoNT-A injection remains to be established.
OBJECTIVES OBJECTIVE
This randomized single-blind pilot study aimed to investigate the efficacy of ES of antagonist muscles as adjunct treatment after BoNT-A injection to plantar flexor muscles in hemiplegic patients with spastic equinus foot.
METHODS METHODS
After BoNT-A injection at triceps surae, patients were randomly allocated to 2 groups: group 1, single ES session on injected muscles plus 5 sessions of ES on antagonist muscles, and group 2, single ES session on injected muscles alone. Both groups underwent daily physical therapy for 60min for 2 weeks (5 days/week). Assessments were performed before treatment (T
RESULTS RESULTS
The 30 patients enrolled were randomly allocated to the 2 groups: 15 in group 1 and 15 in group 2. At T
CONCLUSIONS CONCLUSIONS
ES of antagonist muscles does not improve clinical outcomes in the post-stroke spastic equinus foot after BoNT-A injection.

Identifiants

pubmed: 31228593
pii: S1877-0657(19)30075-2
doi: 10.1016/j.rehab.2019.06.002
pii:
doi:

Substances chimiques

Neuromuscular Agents 0
Botulinum Toxins, Type A EC 3.4.24.69

Types de publication

Comparative Study Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

214-219

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Alessio Baricich (A)

Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy; Physical Medicine and Rehabilitation, University Hospital "Maggiore della Carità", Novara, Italy. Electronic address: alessio.baricich@med.uniupo.it.

Alessandro Picelli (A)

Neuromotor and Cognitive Rehabilitation Research Center, Department of Neurological, Biomedical and Movement Sciences, Università di Verona, Verona, Italy.

Stefano Carda (S)

Neuropsychology and Neurorehabilitation Service, Department of Clinical Neuroscience, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Nicola Smania (N)

Neuromotor and Cognitive Rehabilitation Research Center, Department of Neurological, Biomedical and Movement Sciences, Università di Verona, Verona, Italy.

Carlo Cisari (C)

Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy; Physical Medicine and Rehabilitation, University Hospital "Maggiore della Carità", Novara, Italy.

Andrea Santamato (A)

Department of Physical Medicine and Rehabilitation, "OORR Hospital", Università di Foggia, Foggia, Italy.

Alessandro de Sire (A)

Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy; Rehabilitation Unit, "Mons. L. Novarese" Hospital, Moncrivello, Vercelli, Italy.

Marco Invernizzi (M)

Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH